IMARC Group’s latest report, titled “Bifurcation Lesions Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027,” finds that the global bifurcation lesions market size reached US$ 2.2 Billion in 2021. Bifurcation lesions refer to a condition that occurs when a coronary artery narrows adjacent to and involving the origin of a major side branch. They are caused by plaque deposits comprised of fat. They can be detected via diagnostic imaging techniques, such as computed tomography coronary angiography (CTCA) and invasive coronary angiography (ICA). Some commonly used treatment techniques include analysis, procedure duration, X-ray exposure, and long-term follow-up. Since these lesions increase the risk of heart attacks and stroke in patients, bifurcation lesions treatment solutions are gaining immense traction across the globe.
Global Bifurcation Lesions Market Trends:
The rising incidences of coronary artery disease (CAD) have led to an increased risk of bifurcation lesions, which represents the primary factor driving the market growth. Moreover, the expanding geriatric population that is more prone to developing such medical conditions is acting as another significant growth-inducing factor. In addition, governments of various countries are taking favorable initiatives for reimbursement and insurance coverage. In line with this, the declining risks associated with bifurcation lesions treatment due to the surging number of skilled healthcare professionals have augmented the product demand. Besides this, the shifting consumer preferences toward minimally invasive (MI) procedures have propelled market growth. Furthermore, several key players are heavily investing in ongoing clinical trials on stents and balloons for the treatment of bifurcation lesions. Along with this, recent developments in imaging modalities and advancements in devices, adjunctive pharmacotherapy, and vascular access have facilitated the efficient management of complex bifurcation lesion cases, thereby contributing to market growth. Other factors, including the increasing burden of cardiovascular diseases (CVDs) and obesity, ongoing research on novel treatment techniques, the emerging trend of medical tourism, improving healthcare infrastructure, and rising approval of innovative devices, are also providing a positive thrust to the market growth. Looking forward, IMARC Group expects the market value to reach US$ 3.0 Billion by 2027, growing at a CAGR of 5.5% during 2022-2027.
- Based on the types, the market has been classified as one and two stents.
- On the basis of the application, the market has been bifurcated into coronary and peripheral vascular.
- Region-wise, the market has been segmented into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
- The competitive landscape of the market has also been analyzed, with some of the key players being Boston Scientific Corporation, Cardinal Health, Medtronic plc, Spectranetics (Koninklijke Philips N.V.), and Terumo Corporation.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St, Ste
Sheridan, WY (Wyoming) 82801 USA
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800